

# Supplementary Materials: Calcination Improves the in Vivo Efficacy of a Montmorillonite Clay to Bind Aflatoxin G1 in Broiler Chickens: A Toxicokinetic Approach

Roua Rejeb, Siegrid De Baere, Mathias Devreese, Richard Ducatelle, Siska Croubels, Madiha Hadj Ayed, Achraf Ghorbal and Gunther Antonissen

**Table S1.** MRM transitions and MS/MS parameters for AFG1 and the internal standard, <sup>13</sup>C<sub>17</sub>-AFG1.

| Analyte                             | Precursor (m/z) <sup>a</sup> | ion | Product (m/z)      | ions | CE <sup>b</sup> (eV) | Cone (V) | Retention (min) | time |
|-------------------------------------|------------------------------|-----|--------------------|------|----------------------|----------|-----------------|------|
| AFG1                                | 329.1                        |     | 243.0 <sup>c</sup> | 23   | 35                   | 4.38     |                 |      |
|                                     |                              |     | 311.1              | 18   | 35                   |          |                 |      |
| <sup>13</sup> C <sub>17</sub> -AFG1 | 346.1                        |     | 257.1 <sup>c</sup> | 25   | 40                   | 4.38     |                 |      |
|                                     |                              |     | 328.1              | 20   | 40                   |          |                 |      |

Note: <sup>a</sup> m/z = mass-to-charge ratio, <sup>b</sup> CE = collision energy, <sup>c</sup> ion used for quantification.


**Table S2.** Results of the within-run and between-run precision and accuracy evaluation for the analysis of aflatoxin G1 in chicken plasma.

| Theoretical concentration (ng/mL) | Mean concentration ± SD (ng/mL) | Precision, (%) | RSD | Accuracy (%) |
|-----------------------------------|---------------------------------|----------------|-----|--------------|
| 0.50 <sup>a</sup>                 | 0.50 ± 0.01                     | 2.1            |     | -0.6         |
| 0.50 <sup>b</sup>                 | 0.53 ± 0.07                     | 13.0           |     | 6.2          |
| 5.00 <sup>a</sup>                 | 4.88 ± 0.14                     | 3.0            |     | -2.4         |
| 5.00 <sup>b</sup>                 | 5.20 ± 0.68                     | 13.0           |     | 4.1          |
| 50.0 <sup>a</sup>                 | 48.2 ± 1.8                      | 3.7            |     | -3.6         |
| 50.0 <sup>b</sup>                 | 48.3 ± 2.2                      | 4.5            |     | -3.4         |


Note: <sup>a</sup> Within-run accuracy and precision (n=6); <sup>b</sup> Between-run accuracy and precision (n= 3 × 6); SD: standard deviation; RSD: relative standard deviation; Acceptance criteria: accuracy: < 1 ng/mL: -50% to +20%, ≥ 1 to < 10 ng/mL: -40% to +20%, ≥ 10 to < 100 ng/mL: -30% to +10%, within-run precision (RSD<sub>max</sub>): < 1 ng/mL: 30 %, ≥1 to < 10 ng/mL: 25.0%, ≥ 10 ng/mL: 15.0%, between-run precision: < 1 ng/mL: 45%, ≥ 1 to < 10 ng/mL: 32%, ≥ 10 to < 100 ng/mL: 23%, ≥100 ng/mL: 16% [VICH GL49].

**Table S3.** Results of the investigation of the UHPLC-HRMS extracted ion chromatograms (XIC) of a plasma sample taken at (A) 10 min after intravenous administration and (B) 30 min after oral administration of 2 mg AFG1/kg BW for possible phase I and phase II metabolites.

|                 | Concentration<br>(ng/mL ) | Retention<br>time<br>(min) | Calculated<br>monoisotopic<br>mass<br>(m/z) | Observed<br>mass<br>(m/z) | Mass<br>error<br>(mDa) | Mass<br>error<br>(ppm) | Molecular<br>ion   |
|-----------------|---------------------------|----------------------------|---|---------------------------|------------------------|------------------------|--------------------|
| Sample A : AFG1 | 89.2                      | 9.40                       | 329.0661                                    | 329.0676                  | 1.5                    | 4.5                    | [M-H] <sup>+</sup> |
| Sample B : AFG1 | 11.7                      | 9.40                       | 329.0661                                    | 329.0659                  | -0.2                   | -0.6                   | [M-H] <sup>+</sup> |




**Figure S1.** UHPLC-MS/MS chromatogram of (A) a blank plasma sample, (B) a blank plasma sample spiked at the LOQ level (AFG1 concentration: 0.50 ng/ml), a plasma sample taken at (C) 10 min after intravenous administration (AFG1 concentration : 101.7 ng/ml) and (D) 30 min after oral administration of 2 mg AFG1/kg BW (AFG1 concentration : 12.0 ng/ml).




**Figure S2.** UHPLC-HRMS extracted ion chromatogram (XIC) at  $m/z = 329.0661$  of a plasma sample taken (A) before and (B) at 10 min after intravenous administration of 2 mg/kg BW, showing a peak of AFG1 at  $Tr = 9.42$  min (concentration : 89.2 ng/ml); (C) low energy spectrum of the peak at  $Tr = 9.42$  min, showing the  $[M-H]^+$  ion of AFG1 (observed accurate mass at  $m/z = 329.0699$ , mass error: 1.5 mDa or 4.5 ppm); (D) high energy spectrum of the same peak, showing the two major fragment ions of AFG1 at  $m/z = 243.0646$  and  $m/z = 311.0546$ .


(A)



(B)



**Figure S3.** UHPLC-HRMS extracted ion chromatograms (XIC) of a plasma sample taken at (A) 10 min after intravenous administration (AFG1 concentration : 89.2 ng/ml) and (B) 30 min after oral administration of 2 mg AFG1/kg BW (AFG1 concentration : 11.7 ng/ml). The following mass-to-charge ( $m/z$ ) values, corresponding with the theoretical exact mass of the protonated molecular ions  $[M-H]^+$ , were extracted from the total ion chromatogram: (a) parent AFG1,  $C_{17}H_{12}O_7$  : 329.0661; (b) oxidation (+O),  $C_{17}H_{12}O_8$  : 345.0610; (c) reduction (+H<sub>2</sub>),  $C_{17}H_{14}O_7$  : 331.0818; (d) desaturation (-H<sub>2</sub>),  $C_{17}H_{10}O_7$  : 327.0505; (e) hydration (+H<sub>2</sub>O),  $C_{17}H_{14}O_8$  : 347.0767; (f) sulfation (+SO<sub>3</sub>),  $C_{17}H_{12}O_{10}S$  : 409.0229; (g) oxidation + desaturation (+O-H<sub>2</sub>),  $C_{17}H_{10}O_8$  : 343.0454; (h) dehydration (-H<sub>2</sub>O),  $C_{17}H_{10}O_6$  : 311.0556; (i) dihydrodiol formation (+H<sub>2</sub>O<sub>2</sub>),  $C_{17}H_{14}O_9$  : 363.0716; (j) glucuronidation (+C<sub>6</sub>H<sub>8</sub>O<sub>6</sub>),  $C_{23}H_{20}O_{13}$  : 505.0982; (k) glutathione conjugation (+C<sub>10</sub>H<sub>15</sub>N<sub>3</sub>O<sub>5</sub>S),  $C_{27}H_{27}N_3O_{12}S$  ; 618.1394.



**Figure S4.** Correlation between the AFG1 plasma concentrations in 2 chickens that received an (A) oral and (B) intravenous administration of 2 mg/kg BW, after quantitative analysis using the UHPLC-MS/MS and UPLC-HRMS technique, respectively.